PositiveID Corporation Awarded US Patent
20-Mar-2012
|
Source :
|
Visits : 7451
DELRAY BEACH, Fla. - PositiveID Corporation announced today in a press release that it was awarded US Patent No. 8,133,451 for its Dragonfly™ Rapid MDx Cartridge-based diagnostic system, which provides the ability to deliver molecular diagnostic results from a sample in less than 30 minutes. Dragonfly enables accurate diagnostics leading to the potential treatment scenarios at the point of care that are not possible with existing systems.
Dragonfly has been proven effective for a broad range of biological detection including radiation-induced cell damage within the human body, strains of influenza and other common pathogens and diseases such as E. coli, methicillin-resistant staphylococcus aureus (MRSA) and human papilloma virus (HPV). Dragonfly offers the precision of molecular diagnostics in an easy-to-use cartridge format that minimizes the possibility of human error. Typical current molecular diagnostic testing can take hours or even days, requires highly trained personnel and includes multiple handling steps.
William J. Caragol, Chairman and CEO of PositiveID, stated, "With Dragonfly, we have the ability to revolutionize the way healthcare is administered by enabling accurate diagnosis within minutes at the point of care, and before the patient leaves the physician's office. This allows healthcare professionals to prescribe the appropriate treatments immediately, helping to minimize the overuse of antibiotics, and enables rapid treatment and potential monitoring and quarantine measures for serious outbreaks such as certain forms of influenza."
The target markets for Dragonfly range from physicians' offices to urgent care and emergency departments that desire rapid test results and accurate diagnosis while the patient is present, and extend to military field deployments, border locations and others.
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry.